NITI Aayog CEO Amitabh Kant 
Business

India scaling up production of APIs: NITI Aayog CEO Amitabh Kant

India, a global hub for generic drugs, has launched a new scheme to boost production of active pharmaceutical ingredients (APIs) that are greatly dependent on the Chinese supply chain, according to NITI Aayog CEO Amitabh Kant.

migrator

New Delhi

Speaking at the 14th Annual BioPharma and Healthcare Summit, he said India is now gearing up for innovation in its pharmaceutical ecosystem focusing on speedy and scaled up delivery of new vaccines and personalised medicines.

He said India has launched a new scheme to boost production of active pharmaceutical ingredients that are greatly dependent on the Chinese supply chain. “We are planning to do complete manufacturing in India,” he said at the recently-held virtual summit organised by the USA-India Chamber of Commerce.

The summit was attended by major players from the US pharma sector, whose combined annual R&D budget is over $45 billion.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Why CM Vijay silent on law and order crisis: AIADMK

TVK slack in anti-corruption drive: PMK president Anbumani

CM Vijay to skip Delhi book event, says Vaiko

CJP flags detention of protesters in states, asks Centre to honour assurance

Tamil Nadu: Farmers step up pressure on Mekedatu, drought at budget meet